2-(3,5-二甲基哌啶-1-基)乙胺 | 876716-58-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 2-(3,5-二甲基哌啶-1-基)乙胺
• 中文别名: 2-(3,5-二甲基-哌啶-1-基)-乙胺
• 英文名称: 2-(3,5-Dimethylpiperidin-1-yl)ethan-1-amine
• 英文别名: 2-(3,5-Dimethyl-piperidin-1-yl)-ethylamine；1-(2-aminoethyl)-3,5-dimethylpiperidine；2-(3,5-Dimethylpiperidin-1-yl)ethanamine
• CAS: 876716-58-4
• 化学式: C₉H₂₀N₂
• mdl: MFCD06740357
• 分子量: 156.271
• InChiKey: GQSWLZPKSPRYJI-UHFFFAOYSA-N

物化性质

• 沸点：
  208.1±8.0 °C(Predicted)
• 密度：
  0.874±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  29.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  2-[2,8-二(三氟甲基)-4-喹啉基]环氧乙烷 、 2-(3,5-二甲基哌啶-1-基)乙胺 以 乙醇 为溶剂， 反应 0.25h， 以58%的产率得到1-(2,8-bis(trifluoromethyl)quinolin-4-yl)-2-(2-(3,5-dimethylpiperidin-1-yl)ethylamino)ethanol
  参考文献：
  名称：

  Structure–Activity Relationships of 4-Position Diamine Quinoline Methanols as Intermittent Preventative Treatment (IPT) against Plasmodium falciparum

  摘要：

  A library of diamine quinoline methanols were designed based on the mefloquine scaffold. The systematic variation of the 4-position amino alcohol side chain led to analogues that maintained potency while reducing accumulation in the central nervous system (CNS). Although the mechanism of action remains elusive, these data indicate that the 4-position side chain is critical for activity and that potency (as measured by IC(90)) does not correlate with accumulation in the CNS. A new lead compound, (S)-1-(2,8-bis(trifluoromethyl)quinolin-4-yl)-2-(2-(cyclopropylamino)ethylamino)ethanol (WR621308), was identified with single dose efficacy and substantially lower permeability across MDCK cell monolayers than mefloquine. This compound could be appropriate for intermittent preventative treatment (IPTx) indications or other malaria treatments currently approved for mefloquine.

  DOI：

  10.1021/jm200647u
• 作为产物：
  描述：

  3,5-二甲基哌啶 在 lithium aluminium tetrahydride 、 potassium carbonate 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 16.5h， 生成 2-(3,5-二甲基哌啶-1-基)乙胺
  参考文献：
  名称：

  [EN] PYRAZOLOPYRIMIDINES AND THEIR USES AS PDGFR INHIBITORS
  [FR] PYRAZOLOPYRIMIDINES ET LEURS UTILISATIONS EN TANT QU'INHIBITEURS DE PDGFR

  摘要：

  The disclosure is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof. Pharmaceutical compositions comprising compounds of formula (I), as well as methods of their use and preparation, are also described.

  公开号：

  WO2023007009A1

文献信息

• [EN] PROTEIN KINASE INHIBITORS AND USE THEREOF<br/>[FR] INHIBITEURS DE PROTÉINE KINASE ET LEUR UTILISATION
  申请人：MERCK SERONO SA

  公开号：WO2009108670A1

  公开（公告）日：2009-09-03

  Disclosed are benzonaphthyridinyl derivative compounds and analogs thereof, pharmaceutical compositions comprising such compounds and processes for preparing the same. The compounds are useful in the treatment of diseases amenable to kinase signal transduction inhibition, regulation or modulation.

  揭示了苯并萘啶衍生物化合物及其类似物，包括含有这些化合物的药物组合物以及制备这些化合物的方法。这些化合物在治疗对激酶信号传导抑制、调节或调控敏感的疾病中很有用。
• New Esters of 4-Amino-5-chloro-2-methoxybenzoic Acid as Potent Agonists and Antagonists for 5-HT₄ Receptors
  作者：Donglai Yang、Jean-Louis Soulier、Sames Sicsic、Monique Mathé-Allainmat、Béatrice Brémont、Tiziano Croci、Rosanna Cardamone、Giulio Aureggi、Michel Langlois

  DOI：10.1021/jm960320m

  日期：1997.2.1

  hoxybenzoic acid and substituted 1-piperidineethanol were synthesized and found to be potent 5-HT4 receptor agonists in the electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum and the rat esophagus muscle. Monosubstitution of the piperidine ring with Me, OH, NH-Ac, or CONH2 groups gave compounds equipotent to 7a (ML 10302), a 5-HT4 receptor agonist previously reported

  合成了许多衍生自4-氨基-5-氯-2-甲氧基苯甲酸和取代的1-哌啶乙醇的苯甲酸酯，它们在豚鼠回肠的电刺激的肠神经丛和纵肌中是有效的5-HT4受体激动剂。和大鼠食道肌肉。哌啶环被Me，OH，NH-Ac或CONH2基团单取代后，化合物等效于7a（ML 10302），这是先前报道的具有纳摩尔摩尔亲和力的5-HT4受体激动剂。7a，k与5-羟色胺（5-HT）一样有效，但最大响应仅为5-HT的60-80％，表明这些化合物具有部分激动剂特性。在大鼠纹状体中用[3H] GR 113808进行结合测定，发现其中一些化合物对5-HT4受体具有纳摩尔摩尔亲和力（7a，Ki = 1.07 +/- 0.5 nM； 7k，Ki = 1。0 +/- 0.3 nM）。在哌啶环上引入两个甲基导致2-[（（顺式和反式-3,5-二甲基哌啶基）乙基] -4-氨基-5-氯-2-甲氧基苯甲酸酯）的药理学特性发生了显着变化， 7克，小时
• [EN] BROMODOMAIN INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE BROMODOMAINES ET LEURS UTILISATIONS
  申请人：GENENTECH INC

  公开号：WO2016077375A1

  公开（公告）日：2016-05-19

  The present invention relates to compounds of formula (I): [INSERT FORMULA (1)] and to salts thereof, wherein R1, R2, Rc, and Rd have any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of bromodomains. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various bromodomain-mediated disorders.

  本发明涉及式(I)的化合物：[插入式(1)]及其盐，其中R1、R2、Rc和Rd具有规范中定义的任何值，以及其组合物和用途。这些化合物可用作溴结构域的抑制剂。还包括包含式(I)的化合物或其药学上可接受的盐的药物组合物，以及在治疗各种溴结构域介导的疾病中使用这些化合物和盐的方法。
• [EN] POLYCYCLIC TLR7/8 ANTAGONISTS AND USE THEREOF IN THE TREATMENT OF IMMUNE DISORDERS<br/>[FR] ANTAGONISTES DE TLR7/8 POLYCYLIQUES ET LEUR UTILISATION DANS LE TRAITEMENT DE MALADIES IMMUNES
  申请人：MERCK PATENT GMBH

  公开号：WO2017106607A1

  公开（公告）日：2017-06-22

  The present invention relates to compounds of Formula (I) and pharmaceutically acceptable compositions thereof, useful as toll-like receptor 7/8 (TLR7/8) antagonists. In Formula (I), Ring A is aryl or heteroaryl; Ring B is aryl or heteroary; and X is C(R4)2, O, NR4, S, S(R4), or S(R4)2.

  本发明涉及式(I)的化合物及其药学上可接受的组合物，作为Toll样受体7/8（TLR7/8）拮抗剂。在式(I)中，环A是芳基或杂芳基；环B是芳基或杂芳基；X是C(R4)2、O、NR4、S、S(R4)或S(R4)2。
• PROTEIN KINASE INHIBITORS AND USE THEREOF
  申请人：Huck Bayard R.

  公开号：US20110053906A1

  公开（公告）日：2011-03-03

  Disclosed are benzonaphthyridinyl derivative compounds and analogs thereof, pharmaceutical compositions comprising such compounds and processes for preparing the same. The compounds are useful in the treatment of diseases amenable to kinase signal transduction inhibition, regulation or modulation.

  本发明揭示了苯并萘啉衍生物化合物及其类似物，包括含有这些化合物的制药组合物和制备这些化合物的过程。这些化合物可用于治疗易于激酶信号传导抑制、调节或调控的疾病。